SEOUL, July 23 (Korea Bizwire) — Samsung Biologics Co. said Wednesday its second-quarter net profit gained slightly on-year, backed by increased production output at its latest facilities. Samsung Biologics’ net profit for the April-June period gained 2 percent on-year to 324.4 billion won (US$235.1 million), the company said in a regulatory filing. Operating profit rose [...]
SEOUL, May 22 (Korea Bizwire) — Samsung Biologics Co., a biotech arm of South Korea’s Samsung Group, said Thursday it plans to spin off its biosimilar development business to streamline its operations and focus on its core contract development and manufacturing organization (CDMO) services. According to a regulatory filing, the company will establish a new [...]
SEOUL, May 22 (Korea Bizwire) — Samsung Biologics Co., a biotech arm of South Korea’s Samsung Group, said Thursday it plans to spin off its biosimilar development business to streamline its operations and focus on its core contract development and manufacturing organization (CDMO) services. According to a regulatory filing, the company will establish a new [...]
SEOUL, May 21 (Korea Bizwire) — The U.S. Food and Drug Administration (FDA) is currently conducting an on-site inspection of Samsung Biologics Co.’s production facilities in South Korea, industry sources said Wednesday. According to the sources, the FDA launched the inspection at the company’s facilities in Songdo, west of Seoul, and is scheduled to continue [...]
SEOUL, Jan. 14 (Korea Bizwire) — Samsung Biologics Co., a biotech arm of South Korea’s Samsung Group, said Tuesday it has received a contract manufacturing deal worth 2.07 trillion won (US$1.4 billion) from a Europe-based biopharmaceutical firm. In the largest-ever contract manufacturing deal, Samsung Biologics will manufacture a biomedicine for the European company from Dec. [...]
SEOUL, Dec. 18 (Korea Bizwire) – Samsung Biologics announced on December 18 that it will invest in U.S.-based biotech company Generate Biomedicines through the Samsung Life Science Fund, a venture fund established to advance life sciences innovation. The Samsung Life Science Fund, jointly capitalized with KRW 240 billion ($167 million) by Samsung Biologics, Samsung C&T [028260], [...]
SEOUL, Nov. 20 (Korea Bizwire) — Samsung Biologics Co. said Wednesday it has won two new contract manufacturing deals with a combined value of 930.4 billion won (US$667.7 million) from a Europe-based biopharmaceutical firm. The deals, set to last until the end of 2031, are valued at 752.4 billion won and 178 billion won, respectively, [...]
SEOUL, Oct. 22 (Korea Bizwire) — Samsung Biologics Co. said Tuesday it has signed a deal worth US$1.24 billion for contract manufacturing from an Asia-based biopharmaceutical firm. The deal will last until the end of 2037, the company said in a regulatory filing. Other details remained undisclosed under a confidentiality agreement. Samsung Biologics said the [...]
SAN DIEGO, Jun. 4 (Korea Bizwire) – Samsung Biologics, a leading biopharmaceutical company, has unveiled a new platform and customized brand to strengthen its contract development and manufacturing organization (CDMO) capabilities in the biotech drug development arena. At the 2024 BIO International Convention in San Diego, the company introduced its new CDMO platform, S-Tensify, designed to [...]
SEOUL, Jan. 31 (Korea Bizwire) –Samsung Biologics has disclosed that the total compensation package for its employees, including wages and benefits, can reach up to 100 million KRW annually for first-year employees. On January 31, it was revealed that Samsung Biologics had shared a “Total Compensation Statement” with its employees for the first time, detailing [...]